The effects of 5-HT3 receptor antagonists (ondansetron 0.1 mg kg(-1) S
C 30 min; bemesetron 0.03 mg kg(-1) SC 45 min) on nicotine-induced inc
reases in locomotor activity were measured in male Sprague-Dawley rats
. Intermittent daily injections of nicotine (0.3-1.2 mg kg(-1) SC 30 m
in) resulted in increased locomotor activity as measured by photocell
counts. The effect of nicotine was not affected by administration of t
he 5-HT3 receptor antagonists at doses that are reported to block nico
tine- and morphine-induced place-preference conditioning. Neither of t
he 5-HT3 receptor antagonists tested affected activity counts in vehic
le treated animals. Nicotine-induced hyperactivity was blocked by the
dopamine antagonist haloperidol (0.03 mg kg(-1) SC 2 h) and by the nic
otinic antagonist mecamylamine (1 mg kg(-1) SC 1 min). The effects of
a range of doses (0-1 mg kg(-1)) of the 5-HT3 receptor antagonists ond
ansetron, bemesetron, granisetron and tropisetron on hyperactivity ind
uced by 0.6 mg kg(-1) nicotine were then assessed. Only tropisetron at
1 mg kg(-1) attenuated nicotine-induced hyperactivity. To demonstrate
the efficacy of the present range of doses of the 5-HT3 receptor anta
gonists in this study, conditioned taste aversion experiments were con
ducted. Ondansetron (0.1 mg kg(-1)) failed to attenuate a conditioned
taste aversion to saccharin induced by nicotine (0.6 mg kg(-1)), but d
id induce a reduction in saccharin preference in choice tests followin
g three saccharin-ondansetron pairings. This conditioned reduction in
saccharin preference was replicated with this dose of ondansetron and
extended to bemesetron (0.03 mg kg(-1)) and granisetron (0.1 mg kg(-1)
) in a subsequent experiment. Nicotine-induced hyperactivity and place
-preference conditioning are associated with dopamine release in the n
ucleus accumbens. The present data appear to be inconsistent with the
proposal that 5-HT3 receptor antagonists decrease the behavioural effe
cts of increased dopamine release in the nucleus accumbens.